Impact of the indexed effective orifice area on mid-term cardiac-related mortality after aortic valve replacement Sabine Bleiziffer, 1 Ayyaz Ali, 2 Ina M Hettich, 1 Deniz Akdere, 1 Rüdiger P Laubender, 3 Daniel Ruzicka, 1 Johannes Boehm, 1 Rüdiger Lange, 1 Walter Eichinger 1 ABSTRACT Background There has been ongoing controversy as to whether prosthesisepatient mismatch (PPM, defined as indexed effective orifice area (EOAI) <0.85 m 2 /cm 2 ) influences mortality after aortic valve replacement (AVR). In most studies, PPM is anticipated by reference tables based on mean EOAs as opposed to individual assessment. These reference values may not reflect the actual in vivo EOAI and hence, the presence or absence of PPM may be based on false assumptions. Objective To assess the impact of small prosthesis EOA on survival after aortic valve replacement AVR. Methods 645 patients had undergone an AVR between 2000 and 2007 entered the study. All patients underwent transthoracic echocardiography for determination of the actual EOAI within 6 months postoperatively. In order to predict time from surgery to death a proportional hazards model for competing risks (cardiac death vs death from other causes) was used. EOAI was entered as a continuous variable. Results PPM occurred in 40% of the patients. After a median follow-up of 2.35 years, 92.1% of the patients were alive. The final Cox regression model showed a significantly increased risk for cardiac death among patients with a smaller EOAI (HR¼0.32, p¼0.022). The effect of EOAI on the 2e5 year mortality risk was demonstrated by risk plots. Conclusions In contrast to previous studies these EOAI values were obtained through postoperative echocardiography, substantially improving the accuracy of measurement, and the EOAI was modelled as a continuous variable. There was a significantly improved survival for larger EOAIs following AVR. Strategies to avoid PPM should become paramount during AVR.
The concept of prosthesisepatient mismatch (PPM) was first introduced by Rahimtoola, 1 and occurs when the effective orifice area of an aortic valve prosthesis is considered to be too small in relation to a patient's body size. 2 PPM reflects residual aortic stenosis and, consequently, may lead to incomplete left ventricular mass regression and possibly decreased survival after aortic valve replacement (AVR). The majority of studies evaluating the impact of PPM on outcomes following AVR have relied on effective orifice area (EOA) estimations obtained from previously published reference tables. However, individual echocardiographic EOA measurements might more accurately account for interindividual variety in the EOA of patients. Furthermore, the EOA index (EOAI) has predominantly been studied as a categorical variable, whereas its analysis as a continuous variable is likely to be a more appropriate means of establishing its impact on morbidity and mortality following AVR. The aim of our study was to investigate the impact of EOAI on mid-term survival in patients undergoing AVR, analysing EOAI as a continuous rather than categorical variable.
METHODS
We analysed our outpatient clinic database and identified 645 patients who had undergone bioprosthetic primary AVR between July 2000 and January 2007, with at least 6 months of follow-up. These patients had undergone echocardiography for postoperative calculation of the EOAI. Between July 2007 and December 2007, follow-up data were collected from these patients using a questionnaire, and patient survival status was assessed by scrutinising hospital records. Baseline characteristics and operative data are summarised in 
Echocardiography
Echocardiography was performed 6.561.5 months postoperatively. All examinations were performed by a single dedicated and experienced echocardiographer. Echocardiography was carried out using an image Point Hx ultrasound system with a 2.5 MHz transducer (Hewlett Packard, USA). Peak and mean systolic pressure gradients in the left ventricular outflow tract (LVOT) were measured 1 cm below the valve in an apical three-or five-chamber view. Pulsedwave Doppler was used for LVOT measurements and continuous-wave Doppler for the transvalvular measurements. In patients who were in sinus rhythm the three best available signals were averaged. If atrial fibrillation was present a minimum of five measurements was averaged.
EOA was obtained using the continuity equation. 3 EOAI is the EOA indexed to body surface area, where body surface area is derived from the Dubois formula. 4 For descriptive data, PPM was defined as present in patients with an EOAI #0.85 cm 2 /m 2 .
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Left ventricular mass (LVM) was obtained with the PenneCube formula. 10 Data for LVM calculation were complete in 581 patients. A residual left ventricular hypertrophy (LVH) was defined as an indexed LVM of >125 g/m 2 .
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Statistical analysis
This is a retrospective review of a consecutive series of patients who underwent AVR with a bioprosthesis. Data are expressed as mean values 6 standard deviation for continuous variables, and as percentages for categorical variables. We considered time from operation to death as clinical end point. As cardiac death was the event of interest, we treated death due to other (non-cardiac) causes as possible competing risk. Therefore, we used techniques for analysing survival in a competing risk settingdnamely, cumulative incidence functions for estimating the probability of the interesting events, Gray's test 12 for comparing groups, and for multivariate modelling purposes the proportional hazards model for competing risks proposed by Fine and Gray. 13 For modelling competing risks, we used complete cases with regard to the cause of death and the covariates of EOAI, age at time of operation, gender, arterial hypertension, chronic obstructive pulmonary disease, nicotine abuse, diabetes mellitus, coronary heart disease, preoperative ejection fraction, hyperlipidaemia, previous myocardial infarction, previous cardiac surgery, peripheral vessel disease, carotid stenosis, liver disease, gastrointestinal disease, malignant tumour, renal insufficiency, coagulopathy, psychiatric disease, atrial fibrillation and concomitant procedures. Using the proportional hazards model for competing risks, we developed a multivariate prognostic model which contains all the above-mentioned covariates statistically significant in the bivariate models at the 10% level. Further, the model fit (proportional hazards assumption, influential observations) of the resulting multivariate proportional hazards model was assessed by adequate diagnostic tools. Finally, we performed a sensitivity analysis for the subgroup of patients with a body mass index (BMI) of #30 kg/m 2 . All calculations were performed in SPSS (SPSS 16.0) and R (version 2.9.2). Survival analysis with competing risks using categorised EOAI
RESULTS
Effective orifice area measurements
We collected data of 645 patients of whom 630 patients had information on all covariates (97.7% of all patients). A total of 51 events occurred during the follow-up period. Eight patients who died from unknown cause were excluded as they can be assumed to be missing completely at random. This led to a total of 622 patients with 43 events. We observed 25 cardiac deaths and 18 non-cardiac deaths.
As categorisation of the EOAI with a cut-off value of 0.85 cm 2 /m 2 is commonly employed, we present our categorised data here to allow for improved comparison with other studies. The incidence of PPM (EOAI<0.85 cm 2 /m 2 ) in the study population was 39.9% (248/622).
Mean and median follow-up time was 2.66 years and 2.35 years, respectively, with a range from 0.45 to 7.19 years. Cumulative incidence of cardiac death 1 year and 5 years after AVR was 0.8% (95% CI 0.0% to 1.8%) and 5.4% (0.5% to 10.2%) in patients without PPM versus 2.6% (0.5% to 4.6%) and 10.4% (3.9% to 16.8%) in patients with PPM (Gray's test, p¼0.11, see figure 2 ). Cumulative incidence of non-cardiac death 1 and 5 years after AVR was 0.0% (no events observed) and 4.7% (1.3% to 8.1%) in patients without PPM versus 0.4% (0.0% to 1.3%) and 5.6% (0.9% to 10.3%) in patients with PPM (Gray's test, p¼0.68).
Subgroup analysis of non-obese (BMI <30 kg/m 2 ) patients (487 patients with 21 cardiac deaths and 12 non-cardiac deaths) revealed cumulative incidences for cardiac death of 1.0% (0.0% to 2.2%) and 6.9% (0.6% to 13.2%) after 1 and 5 years in patients without PPM versus 2.3% (0.1% to 4.5%) and 12.6% (4.3% to 21.0%) in patients with PPM (Gray's test, p¼0.19, see figure 2 ). Valvular heart disease group.bmj.com on June 5, 2010 -Published by heart.bmj.com Downloaded from A residual LVH of >125 g/m 211 occurred significantly more often in patients with PPM (145/227, 64%) than in patients without PPM (196/354, 55%, p¼0.042) at 6 months after AVR. The cumulative incidence of cardiac death was increased in patients with residual LVH (2.3% (0.7% to 3.8%) and 10.1% (3.9% to 16.3%) at 1 and 5 years versus 0.5% (0.0% to 1.5%) and 4.4% (0.0 to 8.9%) in patients with no residual LVH, p¼0.16). Among patients with residual LVH, those with PPM exhibit a higher cardiac mortality of 4.1% (0.6% to 7.6%) and 16.4% (4.0% to 28.8%) at 1 and 5 years, compared with patients with residual LVH but no PPM (1.3% (0.0% to 2.9%) and 5.9% (0.4% to 11.3%) and Gray's test with p¼0.07, see figure 2 ).
Multivariate survival analysis with competing risks using EOAI as a continuous parameter
For the purpose of multivariate modelling, we did not categorise EOAI to avoid loss of power and other statistical problems. 15 The histogram in figure 3 
Sensitivity analysis in non-obese patients
Adjusted for the predictors age, diabetes mellitus and preoperative EF <50%, the HR for logarithmic EOAI is 0.31 and statistically significant (p¼0.021) (table 4).
Risk plots
Risk plots for four selected patient profiles were developed to illustrate the impact of the EOAI on cardiac death (figure 4). The risk plots indicate the cumulative incidence for cardiac death after 2, 3, 4 and 5 years in relation to EOAI.
DISCUSSION
Although the concept of 'prosthesisepatient mismatch' was introduced almost 30 years ago, there remains no consensus about its impact on clinical outcome. Furthermore, there remains no standardised and universally accepted method for the calculation of PPM.
After weighing the pros and cons, our group considers echo measurements the most accurate method to assess the impact of the EOAI on mortality as opposed to anticipation of EOA. The key method of our study was to incorporate the EOAI as a continuous variable. The final multivariate model demonstrated a significantly increased risk for cardiac death with smaller EOAI after AVR, while the descriptive analysis using categorised EOAI did not reach statistical significance. The effect of EOAI on survival was only significant in the non-obese patients with a BMI<30 kg/m 2 , and the cumulative incidence of cardiac death was strongly increased in patients with residual LVH and PPM.
Suitability of EOA measurements
In a previous investigation undertaken by our group, we demonstrated that EOA estimation from reference charts tabulated using data derived from large-scale echocardiography studies had a sensitivity of 71% and a specificity of 67%, a positive predictive value of 64%, and a negative predictive value of 74% 14 for the anticipation of PPM. These study data again demonstrate that anticipating the EOA by reference tables instead of echo measurements would have led to 31.8% false assignments to PPM/no PPM groups, although this method is assumed to be better than using geometric or in vitro orifice area.
14 A major reason responsible for the difficulty in accurate estimation of EOA is the broad interindividual variety of EOA even when patients are implanted with the same size and type of prosthesis ( figure 1 ). This phenomenon is attributed to patient-specific differences in anatomical features of the aortic root (eg, larger or narrow sinuses of Valsalva) and patient haemodynamics, which are responsible for the significant difference in the opening and closing dynamics of individual prostheses. 16 17 Currently, the majority of studies analysing the impact of PPM on clinical outcome are based on anticipations of PPM. The determination of EOA using reference tables is a valuable tool, particularly for intraoperative prediction of whether a patient is at risk of PPM. Such manoeuvres allowed us to significantly reduce the incidence of PPM.
14 However, the validity of using reference values, which do not account for individual EOA variance, to determine the impact of PPM on morbidity or mortality after AVR, is a subject for discussion. On the other hand, the Doppler-echocardiographic measurement may be influenced by several factors that are not necessarily related to PPM itself, including patient's flow conditions during the echocardiographic measurement, subvalvular acceleration, or measurement errors such as underestimation of LVOT diameter or misalignment of the Doppler beam with transprosthetic flow jet. In addition, immediate postoperative measurements are less likely to be representative as haemodynamics are not well stabilised at such early time points. Patients investigated early Figure 2 Cumulative incidence of death after aortic valve replacement. Top: cumulative incidence of death in the study population (n¼622 patients). Middle: cumulative incidence of death in 487 non-obese patients (body mass index <30 kg/m 2 ). Bottom: cumulative incidence of death in 341 patients with residual left ventricular hypertrophy. Solid black line: cardiac death in patients with prosthesisepatient mismatch (PPM), effective orifice area index <0.85 cm 2 /m 2 ); dotted black line: cardiac death in patients without PPM; solid gray line: non-cardiac death in patients with PPM; dotted gray line: non-cardiac death in patients without PPM. after AVR are more likely to be in a hyperdynamic state, or exhibit tachycardia, which makes assessment of the EOA difficult. Finally, the acoustic window is often of poor quality in the early postoperative period. To exclude the limitations of early postoperative measurements, we used the EAO measurements obtained at a follow-up investigation 6 months after AVR, which we consider representative and reproducible. We assume that errors up to 1 cm 2 that may occur with the use of the mean values, as demonstrated in figure 1 , are unlikely to result with the individual echocardiographic assessment of the EOA. Therefore, our group considered the echo measurements the most accurate method to assess the impact of the EOAI on midterm cardiac-related mortality.
To our knowledge, our study is the largest evaluation of PPM on survival using individual EOAI measurements. Two previous studies identifying PPM as an independent predictor for longterm mortality obtained echocardiographic data at a median follow-up of 6 days, 18 or before discharge. 19 According to the arguments stated above, we question the usefulness of such early postoperative echocardiographic measurements for characterisation of prosthesis function.
Application of categorised EOAI for survival analysis
Using the EOAI as a categorised variable, our data demonstrate a remarkably increased cumulative incidence of cardiac death in patients with PPM (EOAI#0.85 cm 2 /m 2 ) (figure 2). The incidence of non-cardiac death was similar with or without PPM. The findings were not statistically significant at the 5% level, either in the whole cohort or in the subgroups of non-obese patients and patients with a residual LVH. The EOAI is conventionally converted into categories by assigning patients into two groups ('no PPM', 'PPM'), 20e25 three groups ('mild', 'moderate', 'severe PPM'), 5e9 18 or more groups. 19 This is partly driven by predetermination of cut-off values that will provide a significant association between PPM and outcome. This practice may contribute to undesirable statistical consequences like loss of efficiency, biased effect sizes and artificially low p values. 26 undergone AVR (table 3) , while the descriptive analysis using categorised EOAI did not reach statistical significance. Earlier studies by Blackstone did model the indexed orifice area as a continuous variable, 27e29 but used the geometric valve area to determine the presence of PPM. This variable was later proved to be unrelated to postoperative gradients and clinical outcomes. 2 Risk plots for defined patient profiles additionally demonstrated a timedependent effect, as the slope of the curves for mortality risk increased between 2 and 5 years (figure 4). This finding shows that the negative impact of a smaller EOAI on outcome becomes increasingly apparent over time, possibly owing to the failure of left ventricular remodelling over time due to a residual degree of aortic stenosis. Long-term investigations have demonstrated a significant divergence of survival curves after 5 years, suggesting that the effect of PPM might become increasingly influential beyond the 5-year follow-up that was provided in this study. 9 18 30 31 As survival after AVR is certainly affected by multiple factors, we found, furthermore, a significant influence of patient age, diabetes and impaired left ventricular function. The impact of these variables is well recognised in the published literature. 5 9 20 21 23 29 Finally, as survival after surgical AVR is usually excellent, and the number of events is low, adequate proof of an additional effect of PPM or the EOAI on survival largely depends on most accurate methodology, which includes respecting the continuous nature of the EOAI.
Obesity and left ventricular mass
In concordance with a previous study by Mohty et al 30 the effect of EOAI on survival was only significant in the non-obese patients with a BMI <30 kg/m 2 . In patients with a BMI $30 kg/m 2 , the EOA indexed to the body surface area seems to be an inadequate tool for estimating PPM.
An impaired LVM regression generated by higher gradients is assumed to be the main deleterious effect of PPM. 22 Our data showed an increased proportion of patients with a residual LVH of >125 g/m 2 when the EOAI was <0.85 cm 2 /m 2 . Furthermore, the cumulative incidence of cardiac death was strongly increased in patients with residual LVH and PPM (figure 2, NS). LVM regression depends on multiple factors, such as initial LVM, 32 but PPM remains a factor that can be avoided by the surgeon.
CONCLUSIONS
In summary, our aim was to use improved methodology to evaluate the impact of PPM on survival after AVR. This was undertaken using echocardiographically determined EOA measurements and avoiding analysis of EOAI as a categorical variable. Our data demonstrate a clinically relevant, significant impact of smaller EOAIs on cardiac mortality after AVR, particularly in non-obese patients. Survival is certainly influenced by multiple factors, but PPM remains a factor that can be avoided by the surgeon. Therefore, we conclude that our data add important evidence that preventive strategies to avoid PPM during AVR are reasonable. Such strategies may include intraoperative anticipation of the EOA by reference tables, implantation of third-generation prostheses with larger EOAs or annular enlargement in selected patients. Taking into account our previous findings of impaired exercise capacity in patients with PPM, 33 annular enlargement, in particular, may be advantageous for younger patients in whom PPM is predicted.
Further examinations of the effect of PPM on long-term mortality or morbidity should preferably use echocardiographic EOA measurements rather than estimations from reference tables. This would be helpful in avoiding inaccurate determinations of the presence or absence of PPM. 
Limitations
Only patients who had 6 months' follow-up echocardiography at our institution were included in the study. Therefore, operative and short-term mortality was not investigated. This might have created a survival bias as several patients with severe PPM may have died before 6 months. LVM regression could not be included in this study, as there were no preoperative measurements. The data of LVM were complete in only 90% of the patients. As the number of events (25 cardiac deaths) was small, it will be necessary to increase the length of the follow-up of our patient group. The EOA was indexed to patients' body surface area, thus there might be a rationale for using other variables such as fat-free body mass.
